TNBC tumors do not inherently express ER, PgR, and HER2 receptors and are therefore limited to different chemotherapy treatment regimens to which they rapidly develop resistance, causing an observed limited median overall survival (OS) of approximately 14.5 months, in comparison to their HER2-enriched (50.1 months) and luminal (42.9 months) breast cancer-bearing patient counterparts (Hu et al. 2022). The gene discussed is ERBB2; the disease is breast carcinoma.